Giuseppe Di Lorenzo
University of Naples Federico II
CancerInternal medicineUrologySurgeryPathologyOncologyRetrospective cohort studyProstateChemotherapyNeutropeniaRenal cell carcinomaCabazitaxelDiseaseSunitinibProstate cancerBladder cancerDocetaxelRadiation therapyMedicineCohortGastroenterology
99Publications
25H-index
2,134Citations
Publications 98
Newest
#1Gregory R. Pond (McMaster University)H-Index: 72
#2Archana Agarwal (St Vincent Hospital)
Last. Guru Sonpavde (Harvard University)H-Index: 60
view all 17 authors...
Abstract Background PD1/L1 inhibitors are approved as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the outcomes when employing PD1/L1 inhibitors for platinum-ineligible patients are unclear. This retrospective analysis evaluates the clinical outcomes of first line PD1/L1 inhibitors in patients with aUC deemed to be platinum-ineligible. Meth...
Source
#1Giuseppe Di LorenzoH-Index: 34
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 25
Last. Carlo BuonerbaH-Index: 27
view all 29 authors...
INTRODUCTION Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. PAT...
Source
#1Matteo Ferro (IEO: European Institute of Oncology)H-Index: 29
#2Giuseppe Lucarelli (University of Bari)H-Index: 29
Last. Carlo BuonerbaH-Index: 27
view all 20 authors...
Abstract Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, an...
3 CitationsSource
#1Michele Cavaliere (University of Naples Federico II)H-Index: 9
#2Antonella Miriam Di Lullo (University of Naples Federico II)H-Index: 10
Last. Andrea Elefante (University of Naples Federico II)H-Index: 17
view all 8 authors...
Purpose: Aim of the study is to compare the accuracy of unstructured preoperative Computed Tomography (CT) reports from non-tertiary diagnostic centres with intraoperative findings in a large cohort of patients with Chronic Otitis Media (COM) undergone surgery. Methods: From 2012 to 2019, a total number of 301 patients were considered for our purposes. All patients with clinical evidence of COM had preoperative non-contrast high resolution CT scan of the temporal bone in non-tertiary diagnostic ...
Source
#1Luciana BuonerbaH-Index: 2
#2Rossella Di TrolioH-Index: 13
Last. Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 25
view all 12 authors...
Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer. It frequently emerges in the presence of immunosuppression states such as myeloproliferative syndrome (MS). MS is treated with ruxolitinib, a selective JAK1 and JAK2 inhibitor. Avelumab, an anti PDL-1 inhibitor, is the standard treatment for MCC. To date it is unknown if avelumab and ruxolitinib have a synergistic or antagonistic effect when used together. Methods: We have identified all patients diagnosed with MCC, tr...
Source
#1Sabine Schmid (HSG: University of St. Gallen)H-Index: 13
#2Aurelius Omlin (HSG: University of St. Gallen)H-Index: 34
Last. Silke Gillessen (USI: University of Lugano)H-Index: 58
view all 36 authors...
Importance DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition or platinum-based treatments. However, previous trials assessing platinum-based treatments in patients with CRPC have mostly included a biomarker-unselected population; therefore, efficacy in these patients is unknown. Objective To characterize the antitumor act...
1 CitationsSource
2 CitationsSource
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 25
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 34
Last. Riccardo AutorinoH-Index: 68
view all 2 authors...
Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall survival benefit. However, the cardiovascular toxicity associated with prolonged use of these agents should be taken into consideration before initiating therapy.
Source
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 25
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 34
Last. Riccardo AutorinoH-Index: 68
view all 2 authors...
Source
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 34
#1Giuseppe Di Lorenzo (UNIMOL: University of Molise)H-Index: 4
Last. Sabino De PlacidoH-Index: 62
view all 15 authors...
BACKGROUND: To date, the clinical characteristics of coronavirus disease 19 (COVID-19)-infected urologic cancer patients are unknown. METHODS: We have analyzed all patients with prostate cancer undergoing hormonal or chemotherapy treatment and receiving telephone and in person pre-triage between March 1 and 27, 2020, at the Tortora Hospital, Pagani, Italy. RESULTS: Among 72 patients, 48 and 24 were hormone-sensitive (HS) and castration-resistant prostate cancer (CRPC), respectively; 0 HS and 2 (...
4 CitationsSource